Opinion - (2024) Volume 13, Issue 4
Received: 05-Jul-2024, Manuscript No. jio-24-145784;
Editor assigned: 08-Jul-2024, Pre QC No. P-145784;
Reviewed: 19-Jul-2024, QC No. Q-145784;
Revised: 24-Jul-2024, Manuscript No. R-145784;
Published:
31-Jul-2024
, DOI: 10.37421/2329-6771.2024.13.500
Citation: Antonio, Santiago. “Exploring FGFR2 and NOTCH1 Molecular Interactions: Implications for Cancer Therapy.” J Integr Oncol 13(2024): 500.
Copyright: © 2024 Antonio S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Cancer remains one of the most formidable health challenges globally, with molecular interactions within cells often playing critical roles in its development and progression. Among these interactions, those involving Fibroblast Growth Factor Receptor 2 (FGFR2) and NOTCH1 have garnered significant attention. Both FGFR2 and NOTCH1 are crucial signalling molecules that regulate various cellular processes, including proliferation, differentiation and survival. This article delves into the molecular interactions between FGFR2 and NOTCH1, exploring their implications for cancer therapy.
FGFR2 signalling pathway
FGFR2 is a member of the fibroblast growth factor receptor family, which consists of receptor tyrosine kinases. These receptors are activated by binding to Fibroblast Growth Factors (FGFs), leading to receptor dimerization and auto phosphorylation. This activation triggers downstream signalling pathways, such as the MAPK/ERK, PI3K/AKT and PLCγ pathways, which are involved in cell proliferation, survival and differentiation [1,2].
FGFR2 in cancer
Aberrant FGFR2 signaling has been implicated in various cancers, including breast, gastric and lung cancers. Mutations, amplifications and fusions of the FGFR2 gene can lead to its constitutive activation, promoting oncogenesis. Targeting FGFR2 with specific inhibitors has shown promise in clinical trials, highlighting its potential as a therapeutic target [4].
Molecular crosstalk between FGFR2 and NOTCH1
Emerging evidence suggests a complex interplay between FGFR2 and NOTCH1 signalling pathways. This crosstalk can influence various cellular outcomes and has significant implications for cancer therapy.
Mechanisms of Interaction
FGFR2 activation can influence the expression of NOTCH1 ligands, thereby modulating NOTCH1 signalling. Conversely, NOTCH1 signalling can affect the expression of FGFR2 and its downstream targets. Both FGFR2 and NOTCH1 pathways converge on common downstream effectors, such as the MAPK/ERK pathway. Crosstalk at this level can amplify or dampen signalling outputs, affecting cell fate decisions. FGFR2 and NOTCH1 can undergo post-translational modifications, such as phosphorylation and ubiquitination that affect their stability and activity. Crosstalk between these pathways can modulate these modifications, altering the signalling dynamics.
Implications for cancer therapy
Understanding the molecular interactions between FGFR2 and NOTCH1 provides new avenues for therapeutic intervention. Several strategies can be envisioned. Targeting both FGFR2 and NOTCH1 pathways simultaneously may produce synergistic effects, enhancing therapeutic efficacy and overcoming resistance to single-agent therapies. Identifying biomarkers that reflect the status of FGFR2 and NOTCH1 signalling can guide the selection of patients who are most likely to benefit from targeted therapies. Given the context-dependent roles of FGFR2 and NOTCH1 in cancer, therapies need to be tailored to the specific genetic and molecular landscape of each tumour. Several FGFR2 inhibitors are currently in clinical development or have received regulatory approval. These include small molecule tyrosine kinase inhibitors, monoclonal antibodies and FGF ligand traps. Clinical trials have shown promising results, particularly in cancers with FGFR2 alterations [5]. NOTCH1 inhibitors, including γ-secretase inhibitors (GSIs) and monoclonal antibodies targeting NOTCH1 ligands, have been investigated in preclinical and clinical studies. While these inhibitors have shown efficacy in certain cancers, challenges such as toxicity and resistance need to be addressed.
Despite the promising therapeutic potential of targeting FGFR2 and NOTCH1, several challenges remain. Cancer cells can develop resistance to FGFR2 and NOTCH1 inhibitors through various mechanisms, such as secondary mutations and activation of compensatory pathways. Understanding these resistance mechanisms is crucial for developing effective combination therapies. Inhibition of FGFR2 and NOTCH1 signalling can lead to adverse effects, given their roles in normal tissue homeostasis. Strategies to minimize toxicity while maintaining therapeutic efficacy are needed. Reliable biomarkers are essential for patient stratification and monitoring therapeutic responses. Advances in genomics and proteomics hold promise for identifying such biomarkers.
The intricate molecular interactions between FGFR2 and NOTCH1 have profound implications for cancer therapy. By elucidating the mechanisms of crosstalk and developing targeted interventions, we can improve therapeutic outcomes for patients with cancers driven by aberrant FGFR2 and NOTCH1 signalling. Future research should focus on overcoming the challenges of resistance, toxicity and biomarker identification to fully realize the potential of targeting these pathways in cancer therapy.
None.
None.
Journal of Integrative Oncology received 495 citations as per Google Scholar report
